#CEDA $ASXC Forecast AnalysisThis is the Forecast of $ASXC Company
DISCLAIMER: I am not a financial advisor. All content provided on this channel, and my other social media channels/videos/podcasts/posts, is for entertainment purposes only and reflects my personal opinions. Please do your own research and talk with a financial advisor before making any investing decisions.
ASXC
ASXC 1Mtest
Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, economic shortcomings in surgery. The Senhance Surgical System features as the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Morrisville, NC.
ASXC my super trade hand!!!I’ve done my DD on this both in terms of fundamental and technical analysis and this is my super play it is a 2 year play I would say but the potential profit is amazing
ASXC - -The shares of Asensus Surgical (NYSEMKT:ASXC) are heating up again among penny stock investors. The ASXC stock price increased as much as 8% in pre-market trading on Wednesday morning after new analyst coverage was announced.
-Asensus Surgical is a company pioneering “a new standard of surgery for increased control, less variability and consistently superior outcomes.” The company’s offerings are aimed at integrating machine learning and automated intelligence to improve surgical outcomes. Specifically, Asensus’ focus is on laparoscopic surgical procedures.
-Analysts at H.C. Wainwright initiated coverage on ASXC stock today with a “buy” rating. The coverage comes less than two weeks after Asensus released its first-quarter results, reporting revenue of $2.1 million as compared to $600,000 in the three months ended March 31, 2020. Revenue in the first quarter of 2021 included $1.3 million in its Senhance Surgical System sales, $400,000 in instruments and accessories, and $400,000 in services.
ASXC BUY/LONG BIG OPPORTUNITY 2.00 to 8.00++ TICKER CODE: ASXC
Company Name: Asensus Surgical, Inc.
Industry: Healthcare | Medical Devices | USA
Position Proposed: BUY
Technical Analysis
1. Large Inverted Head & Shoulders (Forming)
2. Fibonacci Retracement at 0.786 ( Silver Zone)
3. Falling Wedge / Pennant (Nearly Completed)
4. 1st Take Profit will be at Fibonacci Expansion Safe Take Profit and Flagpole Length
Entry: NOW READY (2.00-2.40)
1st Partial Take Profit: 8.00 (August-October 2021)
2nd Partial Take Profit: 12.10 (Early-Mid 2022)
Full Take Profit: 18.90 (End 2022)
Note that timeline buffered, I would expect Full Take Profit by Early 2022
Looking at Death Cross vs Golden Cross trends from the Past to NThese are my original charting ideas, if you wish to see more details, consider subscribing to my You - tube channel: Here's link to original work:
ASXC ASENSUS SURGICALNice symmetrical triangle. MACD histogram is squeeze, its a sign for a big move. The purple lines are my targets.
short term +60,000% next gen biotech Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia.
